select trial semaglutide cardiovascular outcomes without diabetes 2023 π‘SELECT Trialπ‘ A breakthrough in Cardiology THIS JUST IN~~ GLP1 agonism
Description
In der Literatur wird dieser Mechanismus mit einer strkeren Gewichtsreduktion und einem deutlichen Einfluss auf das Leberfett in Phase-II-Studien in Verbindung gebracht

Gastrointestinal adverse effects may be more pronounced or poorly tolerated in post-surgical patients with altered anatomy

1 In the SUSTAIN program, Ozempic was studied in combination with oral-antidiabetic agents and basal insulin

The manufacturer Novo Nordisk has struggled to meet demand since 2022

How do you take GLP-1s
